Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys
- PMID: 2272024
- DOI: 10.1097/00002826-199010000-00006
Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys
Abstract
We examined the ability of L-DOPA to induce dyskinesias in MPTP-treated and normal squirrel monkeys to establish whether the underlying neuropathology associated with parkinsonism is an absolute requirement or merely promotes the development of drug-induced dyskinesias. Administration of L-DOPA (5-40 mg/kg p.o., following a 60 min pretreatment with carbidopa 2.5-20 mg/kg p.o.) induced a range of dopamine-mediated behaviours including locomotor activity, stereotyped scratching, and climbing in both lesioned and nonlesioned animals. However, the dose-response curves showed a marked (three- to fourfold) shift to the left in lesioned animals, indicating behavioural supersensitivity. In contrast, L-DOPA-induced dyskinesias were only observed in MPTP-treated monkeys. Doses required for induction of dyskinesias were lower than those required to induce climbing. These findings provide further evidence that nigrostriatal damage is essential for the genesis of L-DOPA-induced dyskinesias.
Similar articles
-
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.Mov Disord. 2000 May;15(3):459-66. doi: 10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3. Mov Disord. 2000. PMID: 10830409
-
Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey.Neuroscience. 2002;113(1):213-20. doi: 10.1016/s0306-4522(02)00167-7. Neuroscience. 2002. PMID: 12123699
-
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Mov Disord. 2015 Dec;30(14):1901-1911. doi: 10.1002/mds.26453. Epub 2015 Nov 17. Mov Disord. 2015. PMID: 26573698 Free PMC article.
-
The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias.Brain Res Bull. 2012 Jan 4;87(1):1-9. doi: 10.1016/j.brainresbull.2011.09.013. Epub 2011 Sep 24. Brain Res Bull. 2012. PMID: 21963946 Free PMC article. Review.
-
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].Rev Neurol (Paris). 2000 Mar;156(3):224-35. Rev Neurol (Paris). 2000. PMID: 10740093 Review. French.
Cited by
-
Metabotropic glutamate receptors for Parkinson's disease therapy.Parkinsons Dis. 2013;2013:196028. doi: 10.1155/2013/196028. Epub 2013 Jun 19. Parkinsons Dis. 2013. PMID: 23853735 Free PMC article.
-
Dyskinesias and levodopa therapy: why wait?J Neural Transm (Vienna). 2018 Aug;125(8):1119-1130. doi: 10.1007/s00702-018-1856-6. Epub 2018 Feb 10. J Neural Transm (Vienna). 2018. PMID: 29428995 Review.
-
Clinical aspects and management of levodopa-induced dyskinesia.Parkinsons Dis. 2012;2012:745947. doi: 10.1155/2012/745947. Epub 2012 Jun 3. Parkinsons Dis. 2012. PMID: 22701811 Free PMC article.
-
The use of nonhuman primate models to understand processes in Parkinson's disease.J Neural Transm (Vienna). 2018 Mar;125(3):325-335. doi: 10.1007/s00702-017-1715-x. Epub 2017 Mar 29. J Neural Transm (Vienna). 2018. PMID: 28357564 Review.
-
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.Parkinsonism Relat Disord. 2011 Jan;17(1):34-9. doi: 10.1016/j.parkreldis.2010.10.010. Epub 2010 Nov 11. Parkinsonism Relat Disord. 2011. PMID: 21074478 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources